DEFA14A: Masimo Responds to Politan Capital's Rejection of Board Seat Offer, Aims to Avert Proxy Fight

Masimo publicly responds to Politan Capital's rejection of a board seat offer for their nominee, expressing disappointment and a desire to avoid a costly proxy fight.

Summary

• Masimo's Lead Independent Director, Craig Reynolds, sent a letter to Quentin Koffey of Politan Capital Management LP on May 13, 2024, responding to Politan's rejection of Masimo's offer to appoint Politan's nominee, Mr. Jellison, to Masimo's Board.
• Masimo expressed disappointment that Politan did not engage constructively.
• Masimo believes their settlement proposal was reasonable and addressed Politan's concerns regarding the ability of their director nominees to approve Board actions.
• Masimo is concerned that Politan's proposal to add two additional nominees would effectively give Politan control of the Board without a stockholder vote.
• Masimo views Politan's efforts to oust Mr. Kiani as a threat to stockholder value.
• Masimo hopes to avoid a prolonged and expensive proxy fight that will damage the company.
• Masimo is making the reply public to show stockholders they are working on a solution beneficial to all.
• The communication includes forward-looking statements regarding the 2024 Annual Meeting, the settlement offer, strategic plans, and the potential separation of the Consumer Business.
• Masimo intends to file a proxy statement and GOLD proxy card with the SEC in connection with its solicitation of proxies for its 2024 Annual Meeting.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the ongoing dispute with Politan Capital and the potential for a costly proxy fight. While Masimo is trying to present a positive outlook, the underlying conflict creates uncertainty.

Positives

• Masimo is actively seeking a resolution to the dispute with Politan Capital.
• Masimo is considering the separation of its Consumer Business, which could unlock value.
• Masimo has added four independent directors to the board in the last 11 months.

Negatives

• Politan Capital rejected Masimo's settlement offer, increasing the likelihood of a proxy fight.
• Masimo views Politan's efforts to oust Mr. Kiani as a threat to stockholder value.
• A prolonged proxy fight could damage Masimo's brand and ability to serve patients.

Risks

• Uncertainties regarding a potential separation of Masimo's Consumer Business.
• Uncertainties regarding future actions that may be taken by Politan.
• The potential cost and management distraction attendant to Politan's nomination of director nominees at the 2024 Annual Meeting.

Future Outlook

The company is evaluating the proposed separation of its Consumer Business and the potential benefits of such separation. The company intends to file a proxy statement and GOLD proxy card with the SEC in connection with its solicitation of proxies for its 2024 Annual Meeting.

Management Comments

• Craig Reynolds: 'I am disappointed you have once again decided not to engage with us constructively.'
• Craig Reynolds: 'We have been open, honest and transparent about our plans for Masimo’s future and our vision to maximize value for all of Masimo’s stockholders.'
• Craig Reynolds: 'I view your efforts to oust Mr. Kiani as a threat to stockholder value.'
• Craig Reynolds: 'My sincere hope is that our offer to have Mr. Jellison join our Board will move us past our current disagreements and avoid a prolonged and expensive proxy fight that will deeply damage our brand, our Company and our ability to serve patients.'

Industry Context

This announcement highlights the increasing prevalence of activist investors (like Politan Capital) seeking board representation and strategic changes in publicly traded companies. The outcome of this situation could set a precedent for future engagements between companies and activist investors in the healthcare technology sector.

Comparison to Industry Standards

• Proxy fights are a common occurrence when activist investors seek to influence company strategy, similar to situations involving companies like Procter & Gamble and Nelson Peltz's Trian Fund Management.
• The potential separation of Masimo's consumer business mirrors moves by other diversified healthcare companies to streamline operations and focus on core competencies, such as Johnson & Johnson's spin-off of its consumer health division (Kenvue).

Stakeholder Impact

• Shareholders face uncertainty due to the proxy fight and potential strategic changes.
• Employees may be affected by the potential separation of the Consumer Business.
• Customers could experience disruptions if the proxy fight impacts Masimo's operations.
• The outcome of the proxy fight could influence Masimo's relationships with suppliers and creditors.

Next Steps

• Masimo will file a proxy statement and GOLD proxy card with the SEC.
• Masimo and Politan Capital may continue negotiations to reach a settlement.
• Stockholders will vote on the director nominees at the 2024 Annual Meeting.

Key Dates

Keywords

Masimo, Politan Capital, Proxy Fight, Board Seat, Settlement Offer, Director Nominees, Annual Meeting, Consumer Business Separation, Craig Reynolds, Quentin Koffey